Mosapride SR Pellets are pharmaceutical-grade sustained-release multiparticulate pellets containing Mosapride as the active ingredient. Mosapride is available as the citrate salt in pharmaceutical applications. The active moiety has the molecular formula C₂₁H₂₅ClFN₃O₃ and molecular weight 421.89 g/mol. Mosapride citrate has CAS Number 112885-42-4, molecular formula C₂₇H₃₃ClFN₃O₁₀, and molecular weight 614.02 g/mol.
Mosapride SR Pellets are designed as a sustained-release multiparticulate formulation, where the pellet matrix or functional coating controls the release of the active ingredient. The pellet system can be developed with controlled particle size, active loading and release characteristics according to the intended formulation requirements.
Commercial pharmaceutical pellet portfolios document Mosapride in sustained-release, immediate-release and enteric-coated pellet formats, confirming its use as a multiparticulate formulation platform. However, a universal commercial strength for Mosapride SR Pellets could not be established from reliable sources, so the final SDP strength should be entered only from the approved SDP product specification or COA.
Mosapride SR Pellets are suitable for capsule filling, multiparticulate oral dosage-form development, formulation development and bulk pharmaceutical manufacturing. The sustained-release characteristics can be adjusted through suitable pellet coating or matrix technology while maintaining appropriate pellet quality and content uniformity.
Mosapride SR Pellets are designed for oral formulations requiring a controlled release profile over an extended period.
The multiparticulate format is suitable for incorporation into hard gelatin or suitable capsule dosage forms according to the final formulation design.
Individual pellets can be engineered with controlled release characteristics, providing flexibility in developing sustained-release oral formulations.
Mosapride SR Pellets can be used as a formulation intermediate for pharmaceutical manufacturers developing sustained-release products.
The pellets can be supplied for bulk formulation requirements with active loading, particle-size distribution and release specifications defined according to the approved product specification.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 0.5% |
| Residue on Ignition | NMT 0.1% |
| Individual Impurity | NMT 0.5% |
| Water Content | NMT 0.5% |